ARCHIVES

Taxol Patents Reveal Bristol Strategy to Safeguard Market Against Competitors

This article is from The Cancer Letter archive.

Vol. 23 No. 26 | July 4, 1997

Download PDF Visit The Full Archive

Related Articles

DCE Board Okays Concepts For More Than $6 Million

March 13, 1987

Autologous BMT Equivalent To Allogeneic For Myeloma

December 31, 2010

A Special Report: Language With A Purpose–von Eschenbach’s Four Years at NCI.

May 19, 2006

PET Tracer Drug Approved, Developed At Weill Cornell

September 24, 2004

Detroit’s “Dr. Vee” Honored For 50 Years In Medicine.

November 9, 2001

MRI Network Sought By AACI Nearing Implementation

June 28, 1985